APUS.US Apimeds Pharmaceuticals US, Inc.

Healthcare Capital Markets USA Stocks
2.23 USD
Close of Nov 14, 2026
1.51 40.31
Market cap
USD 3.37M
P/E
-
P/B
0.03x
ROE
-103.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is APUS.US undervalued?

Graham number

The Graham number of Apimeds Pharmaceuticals US, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Apimeds Pharmaceuticals US, Inc. fundamental analysis

No fundamental analysis for Apimeds Pharmaceuticals US, Inc. yet.

Apimeds Pharmaceuticals US, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Full company profile